Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Cash (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Change in Cash for 16 consecutive years, with -$625000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 219.96% to -$625000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 391.57% increase, with the full-year FY2024 number at -$175000.0, up 22.22% from a year prior.
  • Change in Cash was -$625000.0 for Q3 2025 at Harvard Bioscience, down from $1.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $2.3 million in Q4 2021 to a low of -$2.5 million in Q1 2021.
  • A 5-year average of -$78947.4 and a median of -$207000.0 in 2024 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 489.27% in 2021, then surged 5235.71% in 2025.
  • Harvard Bioscience's Change in Cash stood at $2.3 million in 2021, then plummeted by 127.98% to -$636000.0 in 2022, then plummeted by 66.19% to -$1.1 million in 2023, then skyrocketed by 56.39% to -$461000.0 in 2024, then tumbled by 35.57% to -$625000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Change in Cash are -$625000.0 (Q3 2025), $1.9 million (Q2 2025), and $1.4 million (Q1 2025).